American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

AVENUE THERAPEUTICS, INC. (ATXI)

$0.38 -4.75% OTC: ATXI · 15-min delayed

BAY HARBOR ISLANDS, Florida
Public · OTC: ATXI

Visit website Follow

$1.4MRevenue · FY2025

-$2.9MNet income

ATXIOTC

About AVENUE THERAPEUTICS, INC.

AVENUE THERAPEUTICS INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: ATXI
Headquarters: BAY HARBOR ISLANDS, Florida
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: ATXI OTC
SEC CIK: 1644963
EIN: 474113275
SIC: 2834 Pharmaceutical Preparations

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Avenue Therapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/avenue-therapeutics-inc/"><img src="https://americancompanies.com/badge/avenue-therapeutics-inc.svg" alt="Avenue Therapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow AVENUE THERAPEUTICS, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $1.4M
Net income: -$2.9M
Total assets: $2.9M

Source: SEC EDGAR · updated Jun 8, 2026

OTC: ATXI

$0.38 -4.75%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.15 $0.93

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Avenue Therapeutics, Inc. (ATXI) Stock Price

Reported a net loss of $2.9M in FY2025.
Trading 59% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review AVENUE THERAPEUTICS, INC..

Write a review

Newsroom

News about AVENUE THERAPEUTICS, INC.

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference GlobeNewswire Inc. · 2024-06-20 Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) GlobeNewswire Inc. · 2024-05-16 Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. · 2024-05-15 Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds GlobeNewswire Inc. · 2024-04-29 Avenue Therapeutics Announces Reverse Stock Split GlobeNewswire Inc. · 2024-04-24 Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 GlobeNewswire Inc. · 2024-03-25

News & sentiment via Polygon.io

FAQ

Avenue Therapeutics, Inc.: frequently asked questions

Is Avenue Therapeutics, Inc. an American company?

Avenue Therapeutics, Inc. is a US-based company headquartered in Bay Harbor Islands, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Avenue Therapeutics, Inc. headquartered?

Avenue Therapeutics, Inc. is headquartered in Bay Harbor Islands, Florida, United States.

Is Avenue Therapeutics, Inc. publicly traded?

Yes — Avenue Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ATXI on the OTC.

What does Avenue Therapeutics, Inc. do?

Avenue Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore